Predict your next investment

Venture Capital
venbio.com

See what CB Insights has to offer

Investments

71

Portfolio Exits

23

Funds

4

Partners & Customers

1

About venBIO

venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies, with a focus on therapeutics for unmet medical needs.

venBIO Headquarters Location

1700 Owens Street Suite 595

San Francisco, California, 94158,

United States

415-800-0800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing venBIO

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find venBIO in 1 Expert Collection, including CB Insights Healthcare Smart Money Investors - 2020.

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing venBIO

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned venBIO in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest venBIO News

Horizon Technology Finance leads $45m InBrace venture loan facility

Jul 12, 2022

Horizon Technology Finance leads $45m InBrace venture loan facility Submitted 12/07/2022 - 9:23am Horizon Technology Finance Corporation (Horizon), a specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, has closed a $45 million venture loan facility to Swift Health Systems, Inc (dba InBrace), of which Horizon funded $7 million of the initial $10 million draw, and a private investment vehicle managed by Horizon Technology Finance Management LLC, Horizon's advisor, funded $3 million. InBrace is the orthodontic company behind the Smartwire, transforming the teeth straightening process and markedly improving the patient experience. The InBrace Smartwire is fit behind teeth by an orthodontist, making treatment completely hidden so that patients can share their improving smile as teeth are straightening in real time.  The InBrace Smartwire is created from shape memory alloy that continually moves teeth into place using Gentleforce technology. InBrace works like autopilot and doesn't require the painful monthly tightenings of braces or the tray changes and lifestyle inconvenience of plastic aligners.  InBrace is backed by a consortium of well-known investors including: Vivo Capital, Endeavour Vision Ltd, Farallon Capital Management, Marshall Wace, MVM, Novo Holdings, RTW Investments, LP, Soleus Capital, and venBio Partners LLC. The company will use the loan proceeds for general growth and working capital purposes. Like this article? Sign up to our free newsletter Author Profile Related Topics Deals Intelligence

venBIO Investments

71 Investments

venBIO has made 71 investments. Their latest investment was in ImmPACT Bio as part of their Series B on January 1, 2022.

CBI Logo

venBIO Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/20/2022

Series B

ImmPACT Bio

$111M

Yes

15

1/19/2022

Series A

Ceptur Therapeutics

$75M

Yes

5

12/17/2021

Series C

NorthSea Therapeutics

$80M

No

18

11/29/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/16/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/20/2022

1/19/2022

12/17/2021

11/29/2021

11/16/2021

Round

Series B

Series A

Series C

Series A

Series B

Company

ImmPACT Bio

Ceptur Therapeutics

NorthSea Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$111M

$75M

$80M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

5

18

10

10

venBIO Portfolio Exits

23 Portfolio Exits

venBIO has 23 portfolio exits. Their latest portfolio exit was CinCor Pharma on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

4

10/21/2021

IPO

$99M

Public

20

6/25/2021

IPO

$99M

Public

6

4/23/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/5/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

10/21/2021

6/25/2021

4/23/2021

2/5/2021

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

4

20

6

10

10

venBIO Fund History

4 Fund Histories

venBIO has 4 funds, including venBio Global Strategic Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/3/2021

venBio Global Strategic Fund IV

$550M

2

4/3/2020

venBio Global Strategic Fund III

Subscribe to see more

Subscribe to see more

$99M

10

3/1/2017

venBio Global Strategic Fund II

Subscribe to see more

Subscribe to see more

$99M

10

10/31/2012

venBio Global Strategic Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/3/2021

4/3/2020

3/1/2017

10/31/2012

Fund

venBio Global Strategic Fund IV

venBio Global Strategic Fund III

venBio Global Strategic Fund II

venBio Global Strategic Fund LP

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$550M

$99M

$99M

$99M

Sources

2

10

10

10

venBIO Partners & Customers

1 Partners and customers

venBIO has 1 strategic partners and customers. venBIO recently partnered with Ligand Pharmaceuticals on March 3, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

3/30/2018

Partner

United States

Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies

Ligand Pharmaceuticals Incorporated has established multiple alliances , licenses and other business relationships with the world 's leading pharmaceutical companies including Novartis , Amgen , Merck , Pfizer , Celgene , Gilead , Janssen , Baxter International and Eli Lilly .

5

Date

3/30/2018

Type

Partner

Business Partner

Country

United States

News Snippet

Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies

Ligand Pharmaceuticals Incorporated has established multiple alliances , licenses and other business relationships with the world 's leading pharmaceutical companies including Novartis , Amgen , Merck , Pfizer , Celgene , Gilead , Janssen , Baxter International and Eli Lilly .

Sources

5

venBIO Team

5 Team Members

venBIO has 5 team members, including current Managing Partner, Richard Gaster.

Name

Work History

Title

Status

Paul A Brooke

Ithaka Acquisition Corp., Morgan Stanley, and MPM Capital

Founder

Current

Richard Gaster

Pliant Therapeutics, Bloomlife, and Third Rock Ventures

Managing Partner

Current

Corey S. Goodman

Managing Partner

Current

Aaron Royston

Managing Partner

Current

Kurt von Emster

MPM Capital

Managing Director

Former

Name

Paul A Brooke

Richard Gaster

Corey S. Goodman

Aaron Royston

Kurt von Emster

Work History

Ithaka Acquisition Corp., Morgan Stanley, and MPM Capital

Pliant Therapeutics, Bloomlife, and Third Rock Ventures

MPM Capital

Title

Founder

Managing Partner

Managing Partner

Managing Partner

Managing Director

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.